WASHINGTON - U.S. biotechnology firm Novavax Inc. said Thursday its experimental vaccine was about 89 percent effective in preventing the disease caused by the novel coronavirus during a late-stage clinical trial conducted in Britain.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
